Skip to main content

Oligonucleotide GMP Manufacturing

Accelerate Oligos from Clinic to Market

Partnering with Agilent, an experienced contract development and manufacturing organization, will give you the confidence that your clinical and commercial oligonucleotide API will meet appropriate specifications, quality, and purity requirements.

In two state-of-the art cGMP facilities in Colorado, U.S., Agilent produces grams to kilograms of siRNA, antisense, aptamers, sgRNA, and other oligos. We are expanding capacity to take on more programs, increase batch sizes, and address our partners' needs more quickly.

Agilent supports several commercial programs, so you can rely on our expertise throughout clinical trials and commercialization. Accelerate speed to clinic and market, scale chemical processes, and produce high-quality oligo API with us.

Refine By

Products

|
|

Sort Alphabetically

Filter by
Filter Content Selection Tool

Need Help? Find products using our Selection Tool.

Featured Videos
Return to top
Featured News

Agilent to Acquire North American CDMO BIOVECTRA

Agilent Technologies signed a definitive agreement to acquire BIOVECTRA, a leading specialized contract development and manufacturing organization, for $925 million. Based in Canada, BIOVECTRA produces biologics, highly potent active pharmaceutical ingredients, and other molecules for targeted therapeutics. This expands Agilent’s end-to-end biopharma solutions that accelerate drug discovery, development, and manufacturing.

Featured Training & Events

Join Agilent at TIDES Europe 2024

Location:

Hamburg Congress Center, Hamburg, Germany

Date: 2024
Events

0 product selected.

Clear All